# Metformin and Dietary Restriction to Prevent Age-related Morbid Events in People With Metabolic Syndrome

> **NCT02960711** · PHASE3 · COMPLETED · sponsor: **Fondazione IRCCS Istituto Nazionale dei Tumori, Milano** · enrollment: 1600 (actual)

## Conditions studied

- Metabolic Syndrome

## Interventions

- **DRUG:** Metformin Hydrochloride 850 MG Oral Tablet [Glucophage]
- **DRUG:** Ludipress, mg stereate, micronized hydrated silica, talcum

## Key facts

- **NCT ID:** NCT02960711
- **Lead sponsor:** Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-02
- **Primary completion:** 2019-07
- **Final completion:** 2019-07
- **Target enrollment:** 1600 (ACTUAL)
- **Last updated:** 2021-09-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02960711

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02960711, "Metformin and Dietary Restriction to Prevent Age-related Morbid Events in People With Metabolic Syndrome". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02960711. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*